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Abstract
Introduction: We aimed to investigate whether the effect size of the systemic lupus erythematosus (SLE) risk
alleles varies across European subpopulations.
Methods: European SLE patients (n = 1,742) and ethnically matched healthy controls (n = 2,101) were recruited at
17 centres from 10 different countries. Only individuals with self-reported ancestry from the country of origin were
included. In addition, participants were genotyped for top ancestry informative markers and for 25 SLE associated
SNPs. The results were used to compare effect sizes between the Central Eureopan and Southern European
subgroups.
Results: Twenty of the 25 SNPs showed independent association with SLE, These SNPs showed a significant bias
to larger effect sizes in the Southern subgroup, with 15/20 showing this trend (P = 0.019) and a larger mean odds
ratio of the 20 SNPs (1.46 vs. 1.34, P = 0.02) as well as a larger difference in the number of risk alleles (2.06 vs. 1.63,
P = 0.027) between SLE patients and controls than for Central Europeans. This bias was reflected in a very
significant difference in the cumulative genetic risk score (4.31 vs. 3.48, P = 1.8 × 10-32). Effect size bias was
accompanied by a lower number of SLE risk alleles in the Southern subjects, both patients and controls, the
difference being more marked between the controls (P = 1.1 × 10-8) than between the Southern and Central
European patients (P = 0.016). Seven of these SNPs showed significant allele frequency clines.
Conclusion: Our findings showed a bias to larger effect sizes of SLE loci in the Southern Europeans relative to the
Central Europeans together with clines of SLE risk allele frequencies. These results indicate the need to study risk
allele clines and the implications of the polygenic model of inheritance in SLE.
Introduction
The systemic lupus erythematosus (SLE) genetic compo-
nent has been partially elucidated thanks to large studies
that have uncovered more than 30 loci reaching very
convincing disease association [1-12]. These studies
have shown that a large fraction of the SLE loci (such as
STAT4, TNFSF4 or BLK) are shared in the different eth-
nic groups; however, other loci are not (such as PTPN22,
which is exclusive of Europeans). These latter loci can be
due to the absence or rarity of the polymorphism in one
of the ethnic groups (as for PTPN22, which is absent in
Asians), but other SLE loci show a similar frequency in
discordant populations (as for PXK or FCGR2A). Possible
explanations for these conflicting results have been envi-
saged, including differences in linkage between the causal
polymorphism and the analysed SNPs, limitations of
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study design, or differences in the interactions with other
genetic loci or with environmental exposures [13].
Gene-gene interaction could be behind the observation
that SLE loci show variability in effect sizes in function of
the genetic background. For example, the Amerindian
genetic background is associated with a higher effect size
of several SLE loci in Hispanics [14]. We wondered
whether genetic heterogeneity of this type could exist
among European subjects. Support for this hypothesis is
provided by the recent evidence of differences in SLE
clinical features among Europeans [15-17] and by
opposed results of SLE association with PDCD1 [18,19].
Notably, these two observations showed a North-South
axis of variations, which is the main axis of European
population differentiation [20-23].
Our study included 25 top-associated SNPs in the bet-
ter known SLE loci studied in 1,742 patients with SLE
and in 2,101 controls from 17 collections recruited in 10
European countries, each of them with homogeneous
local ancestry. The results showed a bias to larger effect
sizes of the risk alleles in the Southern Europeans relative
to the Central Europeans. We also found clines of risk
allele frequencies.
Materials and methods
Patient data
We used DNA samples from European SLE patients and
ethnically matched healthy controls recruited at 17 cen-
tres from 10 different countries (Table 1). Most of these
samples have already been described [24,25]. Each
recruiting centre was asked for about 100 patients with
SLE according to the revised American College of Rheu-
matology classification criteria [26] and for about 100
controls, producing a total of 1,742 cases and 2,101 con-
trols. Only individuals with self-reported ancestry from
the country of origin were included. All participants gave
their written informed consent to participate and the
study was approved by the relevant ethics committees.
Genotyping
DNA samples were amplified in a multiplex PCR with the
KAPA2G fast HotStart (Kapa Biosystems, Woburn, MA,
USA) in a final volume of 10 μl (20 ng genomic DNA),
using 3 mM MgCl2 and 0.2 μM each primer. Products
were purified by Exo-SAP digestion with exonuclease I
(Epicentre, Madison, WI, USA) and shrimp alkaline
phosphatase (GE Healthcare, Barcelona, Spain). Subse-
quently, single-base extension reactions were performed
with the SNaPshot Multiplex kit (Applied Biosystems,
Foster City, CA, USA). The genotyping call rate success
of the newly studied SNPs was 99.12%. Sequences of pri-
mers and probes are available from the authors upon
request.
Selection of SNPs
Six ancestry informative markers (AIMs) were selected
(see Table S1 in Additional file 1). Three of these are
the most informative AIMs in differentiating Northern
Europeans from Southern Europeans according to a
large study [22]. Another two AIMs are the most infor-
mative for East-West place of origin according to the
same study [22]. rs12913832 is a SNP associated with
large differences in frequency across Europe and unre-
lated to the previous [23]. In addition, we used genotype
data from another 25 SNPs tagging 22 SLE loci reported
in large European studies (see Table S1 in Additional
file 1). These included nine SNPs in nine SLE loci we
had already replicated and that made up the first phase
of the current study [24]. We selected 14 additional
SNPs for de novo genotyping in our samples. These
SNPs were the top SLE-associated SNPs in large pre-
vious studies [2,3,7,27,28]. Not all of them have reached
a genome-wide association level, but they are considered
solid because they were found in large studies and with
an odds ratio (OR) of the risk allele > 1.15 in at least
one study. These 14 SNPs together with two IRF5 SNPs
we had already studied [25] made up the 16 SNPs
included in the second phase of our study.
Statistical analysis
Analysis of results was based on R and Statistica 7.0
(StatSoft, Tulsa, OK, USA). Conformity with Hardy-
Weinberg equilibrium was tested in control samples.
Allele frequencies of the AIMs were compared between
patients and controls from each collection with 2 × 2
contingency tables. We created a global score by sample
collection for the North-South axis of European popula-
tion differentiation (N/S score) with the allele frequencies
of the AIMs. First, we defined AIM allele frequencies as a
function of the allele more common in Northern Eur-
opean populations. The most informative, nonredundant
three AIMs were then selected. Finally, as a normalisa-
tion step we rescaled the frequencies from each of these
three AIMs to 0 to 100%. This was done by considering
0% the frequency in the sample collection where it was
less abundant and 100% the frequency where it was most
abundant. The rescaled values of the three AIMs were
averaged to obtain a combined normalised unique score
for each collection.
Case-control allele frequencies were compared with
fixed-effects and random-effects models stratifying by
sample collection. For the fixed-effect model, the Man-
tel-Haenszel approach was used. For the random-effect
model, an inverse variance meta-analysis approach was
followed. Heterogeneity of effect sizes was evaluated
with the inconsistency parameter I2 derived from the
Cochran Q statistic. A high, moderate and low level of
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inconsistency was attributed to levels of I2 over 75%,
50% and 25%, respectively, as described previously [29].
Distributions of ORs in Central European and Southern
European populations were compared with the binomial
distribution. Geometric mean (Gmean) values of the ORs
were obtained and compared. The sum of SLE risk alleles
was obtained for the 20 SNPs showing independent asso-
ciation with SLE. The sum of genetic risk scores (GRSs)
was also calculated for the same 20 SNPs. The total GRS
for each patient with SLE was the sum of the products of
the natural logarithm of the OR by the number of risk
alleles at each locus that was carried by this patient. The
ORs used to calculate GRS were the specific Mantel-Haens-
zel ORs for the corresponding European subgroup. The
Gmean OR, mean of sum of risk alleles and mean cumulative
GRS values were compared between groups with Student t
tests. Correlation between the N/S score and sum of risk
alleles or the mean of the natural logarithm of the OR was
analysed with the weighted Pearson correlation coefficient.
The threshold for significance was set at P ≤ 0.05.
Results
Analysis of population differentiation
Our study included samples from 1,742 patients with
SLE and 2,101 healthy controls recruited in 17 centres
(Table 1). Recruiters at each centre asked the patients
and the controls for their ancestry, and only those
reporting uniform known ancestry from the respective
country were included. In addition, we checked with six
top AIMs informative for European population differen-
tiation whether there were differences between cases
and controls from each recruitment centre. Five of the
six AIMs provided completely independent information
(pairwise r2 between them < 0.03) - only rs6730157 and
rs4988235 were redundant (r2 = 0.85). This analysis
showed significant differences in the samples from two
collections, the Czech Republic and Belgium. Conse-
quently, these two collections of samples were discarded
from all subsequent analyses.
Next, we divided the remaining 15 collections follow-
ing the major axis of European population differentia-
tion, the North-South axis. According to previous
studies we expected two groups [20-22]: one with all
samples from Central Europe, with samples from the
Netherlands, Germany, Hungary and Slovakia (383
patients with SLE and 463 healthy controls); and a sec-
ond with all samples from Portugal, Spain, Italy and
Greece (1,111 patients and 1,432 controls). The AIM
frequencies in samples from each collection were con-
gruent with this division (Table 1). We obtained the
Table 1 Sample collections, proportion of women, frequencies of the three more informative AIMs and North/South
score
DNA sample Women (%) AIM frequency (%) N/S score
Collectiona Control SLE Control SLE rs12913832 rs382259 rs6730157
NL 180 104 59.4 86.5 83.0 77.6 72.5 100.0
BEb 106 147 93.5 90.5
DE 95 90 n.a. 90 77.9 68.1 56.9 80.5
CZb 100 101 32 85.1
SK 93 94 93.5 91.5 72.8 63.8 39.4 64.4
HU 95 95 48.4 90.4 63.4 59.6 39.0 54.9
ES, LCG 145 88 82.9 92 35.4 67.4 45.3 47.6
ES, OVD 200 147 69 91.8 30.5 70.4 45.4 47.2
ES, SCQ 95 109 48.4 96 35.1 68.2 41.3 46.0
ES, BCN 97 90 52.6 91.1 32.6 63.2 41.6 40.5
ES, MAD 281 92 68.8 91.3 33.1 61.9 42.3 40.0
PT 97 100 91.3 95.3 28.7 60.7 39.1 34.6
IT, MXP 106 129 42.5 86.8 47.6 49.1 19.8 26.2
IT, ROM 102 84 55.9 89.7 38.2 51.9 15.3 20.3
GR, AUMS 100 95 92 91.6 36.0 44.0 13.4 11.3
IT, NAP 109 79 100 90.1 38.6 42.2 10.0 9.6
GR, EH 100 98 67 86.7 36.7 38.0 13.5 6.8
Collections are in descending order of N/S score. aCollections from: University Medical Center Groningen, The Netherlands (NL); Université Catholique de Louvain,
Belgium (BE); Hannover Medical School, Germany (DE); Institute of Rheumatology, The Czech Republic (CZ); Martin Faculty Hospital, Slovakia (SK); Albert Szent-
Györgyi Medical and Pharmaceutical Centre, Hungary (HU); Complexo Hospitalario Universitario A Coruña, Spain (ES, LCG); Hospital Universitario Central de
Asturias, Spain (ES, OVD); Hospital Clinico Universitario de Santiago, Spain (ES, SCQ); Hospital Val d’Hebron of Barcelona, Spain (ES, BCN); Hospital 12 de Octubre,
Madrid, Spain (ES, MAD); Hospital Garcia de Orta, Almada, Portugal (PT); University of Milan and Fondazione IRCCS Ospedale Maggiore Policlinico from Milan, Italy
(IT, MXP), Ospedale S. Camillo - Forlanini from Roma, Italy (IT, ROM); Athens University Medical School, Athens, Greece (GR, AUMS); Second University of Naples,
Italy (IT, NAP); and Evangelismos Hospital, Athens, Greece (GR, EH). bThese two collections were not analysed further because of differences in AIM frequencies
between cases and controls.
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N/S score (for the place of each collection on the
North-South axis), which was as expected from geogra-
phical distribution and previous studies [20-22] and was
in agreement with the division we made (Table 1).
Nine SLE susceptibility loci with a Southern bias
We have already replicated association of top SNPs in
nine SLE susceptibility loci in the samples included in
this study (Table 2) [24]. When these SNPs were analysed
separately in the two subgroups, Central European and
Southern European, we found a bias for stronger associa-
tion in the latter (Figure 1A). This bias was observed in
eight of the nine SNPs. This distribution is significantly
different from that expected by chance (P = 0.039), and
was observed with the Mantel-Haenszel OR (Figure 1A)
and with the random-effect meta-analysis OR (see Figure
S1 in Additional file 1). Mantel-Haenszel analysis was
preferred because none of the 18 analyses showed high
heterogeneity and only three showed a moderate level of
inconsistency. It should be noted that none of the SNPs
taken individually was significantly different between the
two groups.
Association analysis of additional SLE loci
We wanted to assess whether the bias found was a gen-
eral phenomenon of SLE loci. We therefore selected 16
SNPs identifying other SLE genetic loci in Europeans
[2,3,7,27,28]. All of the SNPs were genotyped success-
fully and all were in Hardy-Weinberg equilibrium when
analysed by collection (the two IRF5 SNPs have already
been studied in a fraction of the samples [25]). The
combined data showed significant differences between
SLE cases and controls for 12 SNPs (Table 2). All of the
significant differences were in the same direction as ori-
ginally reported. Only four SNPs were similar in cases
and controls, so they were excluded from further analy-
sis. To avoid redundancy, we checked with conditional
logistic regression whether the two associated SNPs in
IRF5, TNFAIP3, TNFSF4 or the two SNPs in the HLA
(rs2187668 and rs3131379) contributed independently to
the association. One of the TNFSF4 SNPs (rs844644)
showed no association when conditioned in the other
TNFSF4 SNP (P = 0.072), and therefore was no longer
considered. On the contrary, the two IRF5, the two
TNFAIP3 and the two HLA SNPs remained associated
and were included in the following analyses.
Stratification of the SLE patients and controls in Cen-
tral Europeans and Southern Europeans showed that two
of the 11 SNPs (rs3131379 in MSH5, P = 0.003; and
rs2187668 in HLA-DQA1, P = 0.046) were significantly
more associated in the Southern subgroup than in the
Central European subgroup in the Mantel-Haenszel
meta-analysis (Figure 1B); but none was significantly dif-
ferent in the random-effects meta-analysis (see Figure S2
in Additional file 1). The Mantel-Haenszel meta-analysis
was favoured because none of the 22 analyses showed
high inconsistency and only five showed a moderate
level. In total, seven of the 11 associated SNPs were
numerically more associated in the Southern European
subgroup (Figure 1B). Only three SNPs were more asso-
ciated in the Central Europeans (rs573775 in ATG5,
rs729302 in IRF5, and rs5754217 in UBE2L3) and one was
equally associated in the two subgroups (rs2205960 in
TNFSF4), but none of these differences were significant.
Southern bias for all of the SLE-associated SNPs together
When the 20 SNPs (nine from the first phase and 11 from
the second) that have shown independent association in
our samples were considered together, a bias towards a
stronger association in the Southern subgroup was
observed both as a significant deviation of the OR from a
random binomial distribution (P = 0.019) and as a signifi-
cant difference between the OR means, which was larger
Table 2 Association results of the 25 systemic lupus
erythematosus SNPs
Mantel-Haenszel analysis
SNP (locus) OR (95% CI) P value Reference
rs1143679 (ITGAM) 1.70 (1.50 to 1.93) 5.16 × 10-17 [24]
rs7574865 (STAT4) 1.52 (1.36 to 1.70) 6.11 × 10-14 [24]
rs13277113 (C8orf13-BLK) 1.34 (1.20 to 1.50) 1.33 × 10-7 [24]
rs2304256 (TYK2) 1.32 (1.18 to 1.47) 1.17 × 10-6 [24]
rs17435 (MECP2)a 1.27 (1.11 to 1.45) 5.57 × 10-4 [24]
rs10798269 (1q25.1) 1.25 (1.11 to 1.39) 6.12 × 10-5 [24]
rs17266594 (BANK1) 1.23 (1.10 to 1.37) 1.92 × 10-4 [24]
rs4963128 (KIAA1542) 1.19 (1.08 to 1.32) 1.31 × 10-3 [24]
rs6445975 (PXK) 1.15 (1.03 to 1.27) 0.02 [24]
rs3131379 (MSH5) 2.25 (1.89 to 2.68) 6.41 × 10-20 -
rs2187668 (HLA-DQA1) 2.17 (1.88 to 2.51) 1.09 × 10-25 -
rs10488631 (IRF5) 2.00 (1.73 to 2.32) 8.38 × 10-21 [25]
rs2230926 (TNFAIP3) 1.99 (1.60 to 2.47) 2.54 × 10-10 -
rs729302 (IRF5) 1.35 (1.20 to 1.49) 1.70 × 10-7 [25]
rs2476601 (PTPN22) 1.34 (1.13 to 1.60) 9.15 × 10-4 -
rs5754217 (UBE2L3) 1.26 (1.13 to 1.42) 7.30 × 10-5 -
rs2205960 (TNFSF4) 1.25 (1.11 to 1.40) 1.32 × 10-4 -
rs6920220 (TNFAIP3) 1.21 (1.07 to 1.37) 2.25 × 10-3 -
rs844644 (TNFSF4) 1.19 (1.08 to 1.32) 7.22 × 10-4 -
rs1801274 (FCGR2A) 1.18 (1.07 to 1.30) 1.27 × 10-3 -
rs573775 (ATG5) 1.17 (1.05 to 1.31) 4.35 × 10-3 -
rs10156091 (ICA1) 1.09 (0.93 to 1.28) 0.3 -
rs4240671 (XKR6) 1.09 (0.98 to 1.19) 0.1 -
rs2667978 (LYN) 1.06 (0.94 to 1.19) 0.3 -
rs6922466 (PERP) 1.02 (0.91 to 1.14) 0.8 -
The first nine SNPs were analysed in the first phase of the study and the
remaining 16 in the second. Results of Mantel-Haenszel analysis are shown. All
odds ratios (ORs) are expressed for the risk allele. Analyses of some of the
SNPs in these samples have already been reported [24,25]. CI, confidence
interval. aAnalysis performed only in women because the locus is in the X
chromosome.
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Figure 1 Bias for a stronger association in Southern Europeans than in Central Europeans. (A) Nine systemic lupus erythematosus (SLE)
loci from Suarez-Gestal and colleagues [24]. (B) Eleven newly studied SLE-associated SNPs. Mantel-Haenszel odds ratio (OR) for the risk allele and
their 95% confidence interval presented in descending order from left to right. *Loci showed significant differences between the two groups.
MECP2 data only from women because it maps to the X chromosome. SNPs used for each locus are detailed in Table 2.
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in the Southern samples (Gmean = 1.46 ± 1.30) than in the
Central European samples (Gmean = 1.34 ± 1.17, P = 0.02).
Because it was possible that a fraction of the effect size
attributed to a SNP is dependent on other SLE-associated
SNPs, we also compared the mean of the OR for each
SNP conditional on all the other SNPs. This analysis
also showed a larger effect size in the Southern subjects
(Gmean = 1.43 ± 1.24) than in the Central Europeans
(Gmean = 1.28 ± 1.18, P = 0.02).
We also analysed our data in a different way by counting
the SLE risk alleles carried by each subject. Although it
was possible to have from zero to 40 risk alleles, none of
the subjects had less than five or more than 24 risk alleles.
The distribution of frequencies stratified by disease status
and by Central versus Southern subpopulations showed a
gradient of values (Figure 2). The lowest number of risk
alleles was observed in the healthy controls from the
Southern European group (mean ± standard deviation =
12.0 ± 2.5). Immediately higher was the number of risk
alleles corresponding to the Central European controls
(12.8 ± 2.7, P = 1.1 × 10-8 vs. the Southern European con-
trols). This group was followed for the Southern European
SLE patients (14.0 ± 2.5, P = 2.0 × 10-17 vs. the Central
European controls) and, finally, for the Central European
patients (14.4 ± 2.8, P = 0.016 vs. the Southern SLE
patients).
The differences in number of risk alleles were not due
to confounding by deviations from Hardy-Weinberg
equilibrium in any of the four sample groups for any of
the SNPs or by differences in call rate between the four
groups (data not shown). We also checked that the dif-
ferences and order hold when only women were ana-
lysed, with the lowest number in Southern controls
(12.0 ± 2.4) followed by Central controls (13.0 ± 2.6),
Southern SLE patients (14.1 ± 2.5) and Central
European patients (14.4 ± 2.8) - showing significant dif-
ferences between each of these groups except the last
two (P = 5.3 × 10-9, P = 2.1 × 10-8 and P = 0.056,
respectively). The same sequence was observed when
the comparison was made in men (Southern controls
5 7 9 11 13 15 17 19 21 23
Number of risk alleles
0
2
4
6
8
10
12
14
16
18
20
%
 Southern controls
 Central E. controls
 Southern SLE
 Central E. SLE
Figure 2 Systemic lupus erythematosus risk alleles in Central and Southern European patients and controls. Distribution of the number
of systemic lupus erythematosus (SLE) risk alleles in Central European and Southern European SLE patients and controls. y axis, percentage of
subjects in each of the four strata with the corresponding total number of SLE risk alleles. Distance-weighted least-squares fitting lines are
presented. White bars and dotted line, Southern European controls; light grey bars and short-slashed line, Central European controls; medium
grey bars and long-slashed line, Southern European SLE patients; dark grey bars and continuous line, Central European SLE patients.
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12.0 ± 2.7 and Central controls 12.7 ± 3.0, P = 0.01;
Southern SLE patients 13.5 ± 2.5, P = 0.036; Central
SLE patients 14.7 ± 2.8, P = 0.027). In this case, the dif-
ferences between groups were all significant in spite of
the small size of the SLE patient groups.
These results showed from a different perspective the
same bias in effect sizes that has been described in the
previous paragraphs, because the difference in number of
risk alleles between SLE patients and controls of South-
ern origin (difference = 2.06, 95% confidence interval =
1.85 to 2.26) was significantly larger than for patients and
controls of Central European origin (difference = 1.63,
95% confidence interval = 1.25 to 2.01; P = 0.027). In
addition, these results showed that the SLE risk alleles
were less frequent in the Southern European subjects
overall, but the difference was significantly more marked
between controls from the Southern and Central sub-
groups (difference = 0.81, 95% confidence interval = 0.53
to 1.09) than between SLE patients from the same sub-
groups (difference = 0.38, 95% confidence interval = 0.07
to 0.69; P = 0.023).
We also compared the cumulative GRS between South-
ern and Central European SLE patients. This parameter
includes information from the sum of risk alleles and
from the OR, and therefore is not independent of pre-
vious comparisons (Figure 3). The mean sum GRS was
significantly larger in Southern European patients than in
Central European patients (4.31 ± 1.17 vs. 3.48 ± 0.93,
P = 1.8 × 10-32). The difference persisted after excluding
the two HLA SLE-associated SNPs from the analysis
(3.74 ± 0.84 vs. 2.92 ± 0.68, P = 2.4 × 10-58).
Finally, we wanted to analyse the mean number of SLE
risk alleles for each sample collection as a function of its
position along the North-South axis of population differ-
entiation (Figure 4). This analysis showed that the num-
ber of SLE risk alleles in controls and in patients with
SLE increased with the N/S score (R2 = 0.67, P = 0.002
for controls; and R2 = 0.45, P = 0.002 for patients). Simi-
larly, the mean of the natural logarithm of OR correlated
with the N/S score (R2 = 0.40, P = 0.012). The gradual
change in function of the score indicates that the pre-
viously performed analyses were not sensitive to the
point used to separate Central European from Southern
European populations.
Frequency clines of the SLE risk alleles
The previous results suggest the possibility of frequency
gradients or clines of SLE risk alleles along the North-
South axis of population differentiation. We therefore
analysed this possibility for each of the SNPs. For this
analysis we only used data from controls because they
are more representative of the general population. None
of the SLE-associated SNPs showed significant linkage
disequilibrium with the AIMs included in this study (all
pairwise r2 between AIMs and SLE-associated SNPs <
0.05). However, 10 SNPs were significantly different
between Central Europeans and Southern Europeans
(Table 3). Five of these showed differences in excess of
5%, including the two SNPs in the HLA region, PTPN22
(which is already known to show a cline in Europe [30]),
BLK and PXK. Eight of the 10 SNPs were more common
in controls from the Central group than from the South-
ern group in accordance with the direction of change
observed with the sum of all risk alleles. The two excep-
tions were the ITGAM and FCGR2A SNPs. These two
SNPs, however, have shown the same bias in effect sizes
as the other eight. We also checked how the SNP fre-
quencies in controls fitted a linear regression as a func-
tion of the N/S score. Results were similar to the
obtained with the Central versus Southern group com-
parisons, except for SNPs with modest differences and
for the SNP in BLK (Table 3).
Discussion
Two main aspects of our results should be highlighted: a
significant bias to larger effect sizes of the SLE susceptibil-
ity loci in subjects from Southern Europe than those from
Central Europe, and a lower frequency of the SLE risk
alleles at these loci in subjects from Southern Europe.
The bias to stronger association among Southern Eur-
opeans was shown with four types of analysis. The first,
comparing the number of SLE loci showing a trend to
stronger associations beyond the expected at random, is
independent of the loci characteristics. In contrast, com-
parison of the mean OR reflects the magnitude of the dif-
ferences in effect size. An advantage of these two analyses
is that they were done with meta-analysis approaches to
account for sample collection factors. Their limitation is
that they convey little information about the nature of the
differences. The next analysis, comparison of the number
of SLE risk alleles carried by each subject, is more infor-
mative but does not account for sample collection effects.
The last analysis, comparison of sum GRS, combines
information from the two previous analyses and is there-
fore not independent. Concordance of results from the dif-
ferent analyses is reassuring.
Further confidence was gained from the gradual change
of the number of SLE risk alleles per sample collection as
a function of the N/S score, implying insensitivity of the
results to the specific partition of Europeans we have
used. It is also important to note that the studies which
identified SLE risk loci were carried out with subjects of
a dominant Northern European ancestry (full references in
Table S1 in Additional file 1), and therefore the stronger
association we have found in Southern Europeans cannot
be attributed to ascertainment bias. In other words, any
bias due to the discovery of SLE loci in Northern-Central
Europeans will favour a stronger effect size in that
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subpopulation, which is the opposite of our findings. This
makes it very unlikely that our results are due to a tighter
linkage disequilibrium between causal SNPs and the stu-
died SNPs in the Southern subjects. All of these considera-
tions support the validity of the our findings. One should
note that it was an average effect, however, because not all
of the SLE risk alleles showed a trend to stronger effect
sizes in the Southern samples and, in most of those that
showed the trend, differences were small and not signifi-
cant when assessed individually.
The second aspect of our results is the differential dis-
tribution of SLE risk alleles, with a lower frequency in
Southern Europeans than in Central Europeans. The dif-
ference was observed both in SLE patients and in con-
trols, but was more marked in the latter. It was maximal
between the subjects from Greece and Italy, on one side,
and those for the Netherlands on the other. All of the
remaining groups were in between. Seven of the SNPs
showed a frequency cline correlating with the N/S score.
Only one of these clines has already been described for
the risk allele of PTPN22 [30].
The existence of allele frequency clines in the Eur-
opean population and their main axis of differentiation
are well established [20-23]. What is surprising about
our results is that the number of SLE risk alleles fol-
lowed a gradient along this axis instead of varying ran-
domly, with some alleles more common towards the
North and others towards the South. This observation
suggests the possible effect of selective forces acting
along the history of the European populations, probably
through resistance to infections [31,32]. These ideas
demand new studies aiming to explore the relationship
of autoimmunity with infection vulnerability.
A notable facet of the cline of SLE risk alleles in our
study was that the difference between Southern Europeans
and Central Europeans is less marked in SLE patients than
in controls. We propose that this is due to the genetic
structure of SLE that makes patients more similar at SLE
loci across European subpopulations than the average
member of the same subpopulations. This hypothesis is
derived from the polygenic model of genetic inheritance
[33], which includes the concept of liability threshold:
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disease appears when the contribution of multiple genetic
factors to disease liability overcomes a threshold. Diseased
subjects are therefore, on average, more similar for the
genes involved in the disease than are the controls. More
complex scenarios with involvement of differential envir-
onmental factors are also possible, however, and the risk
allele of a particular locus could follow a different pattern
because of specific factors besides the generic effect pro-
posed here.
The validity of our results will be reinforced by replica-
tion in other sample collections. This will be particularly
important in relation to the Central European subgroup -
this was the smallest in our study, causing lower precision
in the OR values and lower power to detect differential
effects. Data from additional populations would also be
interesting, in particular from the more extreme European
subpopulations, because coverage of the full European
spectrum would allow detecting additional clines. In addi-
tion, the AIMs we used were sufficient for group-level
analyses but not for classification of individual subjects,
which could have made our analyses more powerful. The
studied AIMs were able to show the European population
substructure along the North-South differentiation, how-
ever, as in the studies where these AIMs were selected
[22,23].
Our study also provides independent replication of SLE
loci. Most of these loci were already strongly established
and do not require comment (full references in Table S1
in Additional file 1). In contrast, four SNPs with previous
solid association were not replicated in our analysis.
Probably the most solid of them is rs10156091 in ICA1.
This SNP was first associated with SLE in a large gen-
ome-wide association scan (GWAS; P = 1.9 × 10-7, OR =
1.32) [3]. This result was confirmed in an even larger
replication study, but with a lower effect size (OR = 1.16,
P = 6.5 × 10-4) [7]. The allelic frequency of this SNP in
controls (10.0%) implies that our study had 97% power to
detect the originally described effect with P < 0.05, but
only 51% power for an OR like that observed in the repli-
cation study.
Also very solid is the record of rs2667978 in LYN.
This was discovered in the same GWAS (P = 5.1 × 10-8,
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OR = 0.81) [3] and confirmed in a large replication
study with European descent samples, but more weakly
(P = 0.016) [34]. However, this association was not con-
firmed in the already mentioned large replication study
where a different SNP was used, rs7829816 [7]. Our
study was powered to detect an effect as that originally
described with P < 0.01. The rs4240671 SNP in XKR6 is
also backed by strong evidence. It was identified in the
same SLE GWAS as ICA1 and LYN with very strong
evidence including five SNPs with P < 5.0 × 10-8 [3].
The association was not uniformly observed across sam-
ple collections in this study, however, and no replication
in any large study has been reported. The only indepen-
dent replication was obtained for one of the SNPs in a
245-family study in Canadians (rs6985109; P = 0.008)
[35]. Our study had enough power to detect the origin-
ally reported association (OR = 0.75) with P < 10-7
given its elevated allele frequency (49%). Finally, the
weakest previous support was for rs6922466 in PERP.
This SNP was associated with SLE (P = 1.0 × 10-4) only
in a large study [28].
Conclusion
Our study has uncovered a bias for stronger effect sizes
of SLE risk alleles in Southern Europeans than in Central
Europeans. This bias was accompanied by a lower fre-
quency of the risk alleles in the Southern European
group. Difference in frequencies was more marked in
controls than in patients with SLE. These results should
be taken into account for genetic studies of SLE and for
understanding the genetic structure of the disease and
the possible presence of autoimmune disease risk allele
clines and their causes. In addition, these results call for
exploration of the assumptions and implications of the
liability threshold concept - in particular, whether a con-
stant threshold is consistent with GWAS data - as well as
for exploration of environmental or other factors that
could explain the effect size bias. Our findings therefore
contribute to define the genetic epidemiology of SLE and
suggest new lines of research for understanding the deep
genetic structure of SLE.
Additional material
Additional file 1: Table S1 presenting a detailed description of all
the SNPs included in the study, and Figures S1 and S2 with random
effect meta-analysis results corresponding to the same data as
Figure 1in the manuscript.
Abbreviations
AIM: ancestry informative marker; CI: confidence interval; Gmean: geometric
mean; GRS: genetic risk score; GWAS: genome-wide association scan; N/S
score: North/South score; OR: odds ratio; PCR: polymerase chain reaction;
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Table 3 Risk allele frequencies in Central and Southern European controls and relationship with the North/South score
RAF (%) RAF vs. N/S score
SNP (locus) Central European Southern European c2 P value rxy Slope P value
rs3131379 (MSH5) 14.9 4.6 4.9 × 10-26 0.92 4.15 2.0 × 10-6
rs2187668 (HLA-DQA1) 15.7 8.7 1.9 × 10-9 0.88 4.93 4.0 × 10-5
rs2476601 (PTPN22) 11.8 6.1 1.5 × 10-8 0.74 4.21 2.7 × 10-3
rs13277113 (C8orf13-BLK) 31.0 23.2 2.2 × 10-6 0.20 0.95 NS
rs6445975 (PXK) 29.0 22.6 7.5 × 10-5 0.66 2.67 0.01
rs1143679 (ITGAM) 11.9 16.7 4.9 × 10-4 -0.59 -4.79 0.03
rs2205960 (TNFSF4) 25.2 20.7 4.9 × 10-3 0.15 1.08 NS
rs1801274 (FCGR2A) 44.5 48.6 0.03 -0.40 -1.25 NS
rs4963128 (KIAA1542) 69.1 65.3 0.03 0.58 2.83 0.03
rs10488631 (IRF5) 11.6 9.3 0.046 0.46 3.64 0.10
rs17435 (MECP2)a 20.9 22.8 NS -0.57 -2.84 0.03
rs573775 (ATG5) 28.2 26.3 NS 0.51 4.10 0.06
rs7574865 (STAT4) 23.3 23.8 NS -0.51 -4.63 0.06
rs6920220 (TNFAIP3) 19.3 17.8 NS 0.49 2.74 0.07
rs10798269 (1q25.1) 66.2 69.0 NS -0.17 -1.16 NS
rs5754217 (UBE2L3) 22.8 20.8 NS 0.16 1.28 NS
rs2304256 (TYK2) 73.1 71.0 NS 0.06 0.23 NS
rs2230926 (TNFAIP3) 3.5 4.3 NS -0.21 -3.42 NS
rs729302 (IRF5) 67.8 69.0 NS -0.00 -0.03 NS
rs17266594 (BANK1) 71.2 70.9 NS 0.32 1.99 NS
Comparison of the risk allele frequencies (RAFs) between Central and Southern European controls, and linear regression of RAFs to the North/South score (N/S
score) of population differentiation (from Table 1). NS, not significant. aAnalysis performed only in women because the locus is in the X chromosome.
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